Open Accessibility Menu

Clinical Trial Information

Cardio-Protective Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients with Type 2 Diabetes

Study Details

We are looking if Saxagliptin and Dapagliflozin, which are FDA approved Diabetes medications, will improve your cardiovascular health. We are looking for patients who are between 30-70 years of age with HbA1c from 7 to 10%, who are taking Metformin and/or Insulin only for their Diabetes.

Primary Sponsor:

Astra Zeneca Pharmaceuticals, LP

Prinicipal Investigator:

Dr Saby Sen, MD, PhD

Contact Phone:

(202) 741-2389
Cardio-Protective Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients with Type 2 Diabetes hawal@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)